Cyclin dependent kinase 4/6 inhibitors (CDK4/6i) are a recently approved class of drugs (February 2015) that target enzymes important in cell division and thus can interrupt the growth of cancer cells [1]. The gene discussed is CDK4; the disease is cancer.